Repligen (RGEN): Bioprocess Growth vs. Rich Valuation
Repligen is showing strong momentum in chromatography, proteins, and analytics, but the stock already prices in a robust recovery. The report supports a Hold as growth improves while valuation remains demanding.
Repligen (RGEN) is a Hold, earning an overall grade of B- as its bioprocessing growth story improves but valuation stays stretched. Our fair value is $185, and the stock looks attractive only below the current quote unless management sustains double-digit growth and integrates BioLife smoothly.
Thesis
Repligen Corporation (RGEN) offers a credible medium-term growth story built around bioprocessing consumables, chromatography, filtration, proteins, process analytics, and the newly acquired BioLife Solutions cell-therapy portfolio. The company produced Q3 2026 revenue of $209.3M, up 11.0% reported and 12.5% organically, while raising full-year 2026 revenue guidance to $844M-$852M and adjusted EPS guidance to $2.05-$2.09.
The investment case rests on three named facts. Chromatography revenue grew more than 50% in Q3, proteins grew more than 40%, and analytics grew 20%. Management also reported a five-year high for capital-equipment orders, with much of the related revenue scheduled for 2027. BioLife adds a cell-therapy platform, and management expects at least $0.05 of 2027 EPS accretion from the transaction.
The main counterweight is valuation. At $172.51, RGEN trades at 64.1x forward earnings, 13.9x enterprise value to revenue, and a 1.3% free-cash-flow yield. The company is recovering from a 2023-2024 earnings downturn, but Q3 2026 GAAP EPS was a loss of $0.68 because of a $41M intangible-asset impairment. This is a strong business recovery priced as a strong business recovery, not a distressed opportunity.
For a moderate-risk investor with a medium-term horizon, the balance of growth, execution, and valuation supports a Hold recommendation. The attractive entry point sits below the current quote, while the business needs continued double-digit growth and successful BioLife integration to justify a materially higher multiple.
Company Overview
Repligen is a Waltham, Massachusetts-based life-sciences company founded in 1981 and listed on Nasdaq under RGEN. It employs approximately 2,000 people and sells across North America, Europe, Asia Pacific, and other international markets. Its products support the manufacture, purification, monitoring, and preservation of biologic medicines.
▌Common Questions
Frequently asked questions
+Is RGEN stock a buy right now?
RGEN is not a Buy right now; it is a Hold. The business is improving with strong chromatography, proteins, and analytics growth, but the valuation already reflects much of that recovery.
+What is RGEN's fair value?
Repligen’s fair value is $185. We arrive at that view by weighing its strong growth outlook against a rich valuation of 64.1x forward earnings and 13.9x EV/revenue, plus the fact that Q3 GAAP EPS was distorted by a $41M intangible-asset impairment.
+Why did Repligen's stock get a Hold rating?
Repligen earned a Hold because the growth story is real, but the shares already trade like a high-quality recovery name. Q3 revenue rose 11.0% reported and management lifted 2026 guidance, yet the stock’s 1.3% free-cash-flow yield and premium multiples limit near-term upside.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
The company operates as a single reportable segment but serves several product families: filtration, chromatography, proteins, and process analytics. Its portfolio includes XCell ATF systems, KrosFlo tangential-flow filtration systems, OPUS pre-packed columns, chromatography resins, Protein A ligands, growth factors, SoloVPE systems, FlowVPE products, and other PATsmart analytics tools.
The business model combines equipment with recurring consumables and services. The 2025 investor presentation showed a revenue mix of 75% consumables and 25% equipment, while services represented 7% of Q3 2026 revenue. That mix gives RGEN exposure to both capital spending and the recurring production volume of biologic drugs.
Business Segment Deep Dive
Filtration remains the largest product family in the available 2025 segment data, representing 27.3% of the reported product-family revenue. Q3 2026 filtration revenue declined 11%, pressured by a gene-therapy program, two ATF customer headwinds, the PolyMem divestiture, foreign exchange, and customer-requested timing shifts for systems deliveries. Full-year filtration guidance is flat to slightly down.
Chromatography produced the strongest Q3 growth rate, with revenue up more than 50%. OPUS columns drove the result, supported by CDMO and biopharma demand and traction in large-scale columns. Management now expects at least 30% chromatography growth for 2026, making this franchise a central driver of the near-term recovery.
Proteins delivered more than 40% growth in Q3, supported by ligands, growth factors, and custom and catalog resins. Management expects mid-teens growth for the full year and extended a supply agreement with Ecolab. The protein franchise represented 6.6% of the available 2025 product-family revenue data, but its growth rate gives it strategic importance beyond its current size.
Process analytics grew 20% in Q3 and reached a record quarter. Consumables and services led the result, while capital equipment remained healthy. Management expects analytics growth of at least 30% for 2026, supported by SoloVPE PLUS, FlowVPX, PAT-enabled systems, and rising customer interest in AI-enabled process development.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The OPUS pre-packed column and KRM chromatography system form one of RGEN's clearest flagship platforms. The combination integrates chromatography hardware with pre-packed columns used in the purification and quality control of biological drugs. Q3 chromatography growth above 50%, including continued traction with large-scale columns, provides direct evidence of current commercial momentum.
XCell ATF is another important platform. The 2025 investor presentation described it as the first and only alternating tangential flow device and cited 10x viable cell density and 20-fold increased yield. The product is designed for process intensification and can scale from pilot to commercial manufacturing. Q3 revenue was affected by two ATF customer headwinds, but management reported the highest systems order quarter in five years.
SoloVPE PLUS adds a quality-control and analytics layer. Management said downstream protein-concentration offerings received recognition under USP Chapter 507, which provides external validation and can reduce adoption barriers. The commercial value is tied to broader deployment across products and sites, followed by a longer-term opportunity for FlowVPX as customers adopt the technology across more workflows.
Innovation & Competitive Advantage
RGEN's competitive advantage comes from products embedded in regulated biopharmaceutical manufacturing steps. The 10-K identifies customer qualification requirements, competition, and product acceptance as material business factors. Once a process uses a qualified filtration, chromatography, protein, or analytics product, changing suppliers can require additional validation and process work.
The BioLife Solutions acquisition broadens that platform into cell-therapy preservation and processing. RGEN completed the acquisition on October 6, 2026, and management said the combination expands cell-therapy capabilities, adds trusted customer relationships, and creates opportunities for commercial cross-selling. The transaction also gives RGEN exposure to CryoStor and related cell-processing products.
Innovation is also moving toward process intelligence. The company has invested in PATsmart products, digital-twin capabilities, data infrastructure, internal AI pilots, and employee AI training. RGEN's 2025 acquisition of 908 Devices' bioprocessing portfolio added Raman spectroscopy, mass spectrometry, biosensing, and electrophoresis capabilities.
The main innovation risk is execution. The 10-K identifies the possibility that new products fail to gain market acceptance or that acquisitions fail to deliver expected benefits. BioLife's value therefore depends on integration, scrap-rate improvement, cross-selling, and sustained cell-therapy demand rather than on the transaction's headline size alone.
Operations & Supply Chain
Operations are transitioning from recovery management to capacity preparation. RGEN opened a training and innovation center in South Korea, expanded its Asia Pacific commercial focus, and is investing in manufacturing automation. Management also described an integrated solutions team focused on customer capacity expansion and onshoring projects.
The 2026 filtration weakness contains a timing element. Management said most systems orders planned for the second half of 2026 were requested for delivery in 2027, creating a hardware backlog. That supports the 2027 recovery case, although revenue recognition depends on customer delivery schedules and manufacturing execution.
BioLife introduces a specific operational improvement opportunity. Management is evaluating ways to reduce CryoStor scrap rates, while more than half of anticipated year-one operating-expense synergies come from public-company and leadership-cost actions. The 10-K also identifies reliance on limited or single suppliers for certain products, manufacturing capacity constraints, and cybersecurity disruption as operating risks.
Market Analysis
RGEN operates in bioprocessing, a subset of the broader life-sciences tools market. Company materials placed the global bioprocessing market at approximately $20B at year-end 2024 and RGEN's addressable market at approximately $12B. Broader market research places the life-science tools market at $164.5B in 2026, with a projected 6.9% compound annual growth rate through 2031.
The most relevant demand drivers are biologic-drug production, process intensification, single-use manufacturing, outsourcing to CDMOs, and new modalities such as cell and gene therapy. RGEN's products address cost, capacity, quality, and time pressures in biologics manufacturing, giving the company exposure to production volume rather than the commercial success of a single medicine.
Process analytics is a particularly attractive market layer. RGEN's Q3 analytics growth of 20%, management's 30% or greater full-year target, and customer discussions around AI-enabled manufacturing all support a shift toward integrated hardware, software, data, and automation. Services are also structurally important, with market research assigning services an 11.4% growth rate in the broader tools market.
The cycle still matters. RGEN reported a recovering market, but filtration revenue declined 11% in Q3 and CDMO revenue fell against a difficult comparison. The contrast between strong consumables demand and delayed equipment revenue shows why the company can post healthy organic growth while individual product families move in different directions.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The 2025 investor presentation showed RGEN's customer mix at 54% biopharma developers, 30% CDMOs, and 15% integrator or other customers. Biopharma customers provide direct exposure to commercial and clinical biologics production, while CDMOs provide exposure to outsourced manufacturing capacity.
Geographic exposure is balanced across North America, EMEA, and Asia Pacific. Q3 2026 revenue mix was approximately 49% North America, 34% EMEA, and 17% Asia Pacific and the rest of the world. North America grew 6%, EMEA grew more than 20%, and Asia Pacific orders reached a new record even though reported revenue faced a difficult comparison.
The product mix was 65% clinical and 35% commercial in the investor presentation. Emerging biotech revenue grew at a mid-single-digit rate in Q3 and at a high-teens rate year to date. New modalities were relatively flat overall in Q3, but cell therapy grew nearly 30%, making BioLife's customer relationships strategically relevant.
Competitive Landscape
RGEN competes with large integrated suppliers including Cytiva, Sartorius, Thermo Fisher Scientific, and Merck Millipore. These companies offer broad portfolios spanning instruments, consumables, process systems, and services. RGEN competes as a more focused bioprocessing specialist.
Specialized competitors include Tosoh Bioscience, Bio-Rad, Avantor, JNC, and YMC in chromatography, resins, filtration, and adjacent consumables. The competitive battleground is shaped by product qualification, yield improvement, process reliability, delivery capacity, and the ability to support customers from development through commercial manufacturing.
RGEN's differentiation is most visible where its products simplify workflows or improve process performance. OPUS columns, XCell ATF systems, SoloVPE PLUS, PATsmart tools, and the BioLife portfolio each address a defined manufacturing or analytics need. The risk is that larger rivals can bundle products and use scale, while specialized rivals can target individual categories with focused innovation.
Macro & Geopolitical Landscape
China is a meaningful growth opportunity and execution risk. RGEN reported more than 40% China revenue growth in Q3 2026 and more than 50% growth year to date. Management cited China's latest five-year biotech plan, which targets industry growth above 20% annually through 2030.
Asia Pacific orders reached a new record in Q3, and year-to-date regional demand grew at a high-teens rate. The South Korea training and innovation center supports the company's effort to serve a market that management described as a leading hub for biologics and CDMO manufacturing. These facts support regional expansion, but China also brings technology-transfer, regulatory, foreign-exchange, and geopolitical exposure.
Foreign exchange reduced Q3 reported growth by just under one percentage point, while the PolyMem divestiture created a similar headwind. Management said tariffs had a de minimis margin impact in Q3 and that tariff refunds were de minimis. The company is also targeting customer onshoring projects, a trend that can support domestic bioprocessing capacity and equipment demand.
The broader market backdrop remains tied to biopharmaceutical investment and outsourcing. RGEN's Q3 results showed a mixed cycle rather than a uniform boom: consumables grew 20%, services grew more than 20%, while equipment revenue declined despite mid-teens order growth. That split is the most useful macro signal for the next phase.
Balance Sheet Health
▌Premium Members Only
Repligen’s balance sheet earns an A- thanks to a solid financial profile that supports ongoing investment, even as the stock’s upside depends more on execution than leverage relief.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Management raised 2026 revenue guidance to $844M-$852M and adjusted EPS guidance to $2.05-$2.09, with chromatography expected to grow at least 30% and analytics at least 30%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Repligen has moved from a difficult 2023-2024 earnings period into a visible operating recovery. Revenue reached a record $209.3M in Q3 2026, adjusted operating margin reached 15.9%, and management raised full-year guidance. Chromatography, proteins, analytics, services, and BioLife provide several independent growth levers.
The investment still requires discipline. Filtration remains soft, Q3 GAAP earnings included a $41M impairment, insiders recorded net selling, and the valuation carries a 64.1x forward P/E. Those facts make entry price important even though the balance sheet, order book, and analyst estimates support a constructive medium-term outlook.
At $172.51, RGEN is a quality growth recovery rather than a bargain. A Hold rating preserves exposure to the company's bioprocessing and cell-therapy opportunity while recognizing that the next leg higher depends on converting orders into revenue, delivering BioLife synergies, and turning strong adjusted results into durable GAAP earnings and cash-flow growth.
+What are the main growth drivers for RGEN?
The biggest drivers are chromatography, proteins, and process analytics. Chromatography grew more than 50% in Q3, proteins grew more than 40%, and analytics grew 20%, while management expects at least 30% growth in both chromatography and analytics for 2026.
+How does BioLife Solutions affect Repligen's outlook?
BioLife adds a cell-therapy platform and broadens Repligen’s exposure beyond core bioprocessing tools. Management expects at least $0.05 of 2027 EPS accretion from the transaction, but the deal still needs successful integration to support a higher multiple.
▌For Active Investors
Want Reports Like This on Any Stock?
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.